Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab + apatinib + S-1 as second-line treatment for metastatic biliary tract cancer
ChiCTR2100041973Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jan 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab, Rivoceranib and tegafur in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Overall survival. Started Jan 2021; status: recruiting.
02
Drugs
camrelizumabRivoceranibtegafur
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2100041973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041973.